Doc Nouvellon Joins DEA's Naughty List for Substance Shenanigans
Published Date: 10/20/2025
Notice
Summary
Dr. Chantal F. Nouvellon’s case decision affects healthcare providers by clarifying important rules about her professional status. This decision sets clear expectations and may impact how similar cases are handled in the future. No immediate money changes, but it’s a big deal for anyone involved in related medical licensing matters.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Decision clarifies physician licensing rules
If you are a healthcare provider, the Department of Justice/Drug Enforcement Administration Decision and Order in Dr. Chantal F. Nouvellon’s case clarifies rules about her professional status and sets expectations for how similar medical licensing cases may be handled. The decision does not state any immediate changes to money, fees, or payments.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-19599 — Ali Elhorr, M.D.; Decision and Order
Dr. Ali Elhorr faced a formal decision that affects his professional status, with important consequences for his medical practice and reputation. This order sets clear rules and timelines he must follow, impacting his career and possibly his income. Anyone involved in medical licensing or healthcare oversight should pay attention to these changes.
Next: 2025-19601 — Debt Management Advisory Committee Meeting
The Debt Management Advisory Committee is meeting to talk about how the government handles its money and debt. This affects taxpayers and anyone interested in how the U.S. manages borrowing and spending. They’ll discuss new ideas and plans that could impact budgets and timelines soon.